Heier JS, Khanani AM, Quezada Ruiz C, Basu K, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022 Jan 21. pii: S0140-6736(22)00010.
PMID: 35085502